Summary

Under the circumstances of increasingly high R&D costs of new drugs worldwide, the contract research organization (CRO) industry has developed rapidly in recent years thanks to its advantages of shortening the R&D cycle and cost saving. In 2010, the global market size of CRO achieved RMB36 billion, which undertook nearly one third of the R&D of new drugs. CRO industry started relatively late in China, and still in its initial stage with only a few business varieties. In China, the market size of CRO was merely USD2.6 billion (about RMB16.9 billion) in 2010. However, with rapid development, currently there are almost 500 CRO enterprises in China.

Although there are many CRO enterprises in China, large-scale enterprises are less than 10 companies. WuXi AppTec and ShangPharma, two NYSE listed companies, are the largest CRO enterprises in China. WuXi AppTec is the leading enterprise in domestic CRO industry, whose clients include 9 of the top 10 pharmaceutical enterprises worldwide. In Jan. 2008, it successfully acquired AppTec Laboratory Services Inc. for USD151 million, initiating the overseas expansion of Chinese CRO enterprises.

ShangPharma is the second largest CRO enterprise in China. It has over 100 enterprise and academic research institution clients, including the top 10 pharmaceutical enterprises in the world. With the aim to enhance its R&D strength, ShangPharma plans to construct cGMP base and laboratory service building with the funds raised from its IPO in 2010.

Currently, most of the CRO enterprises can only accomplish a single section in the R&D process, therefore, in order to complete the industry chain and enhance the competitiveness, M&A and setting up industry alliance has become a trend in China's CRO industry. From 2007 to Apr. 2011, there were at least 6 M&A cases in the CRO industry of China. As of Apr. 2011, there were five biopharmaceutical CRO industry alliances in China, including Alliance of Bio-Box Outsourcing, China, Zhongguancun Bio-pharmaceutical R&D Outsourcing Alliance, Shanghai Pudong Bio-Pharmaceutical R&D Outsourcing Service Alliance, CROSA and Chengdu Bio-pharmaceutical R&D Outsourcing Alliance. Having witnessed the advantage of CRO alliances in China, foreign companies participated in as well. For instance, the European company NovaSecta joined CROSA.

Table of Contents

1.Overview of CRO Industry
1.1 Definition & Classification
1.2 Industry Background

2. Development Environment of CRO Industry in China
2.1 International Environment
2.2 Industry Environment
2.3 Policy Environment

3. Market Analysis of CRO Industry in China
3.1 Status Quo
3.2 Market Size
3.3 Competition Pattern
3.4 Prospects
3.4.1 Specialized Division of Labor
3.4.2 Low Entry Barriers
3.4.3 Huge Demand
3.5 CRO Industry Alliances in China
3.5.1 ABO
3.5.2 Zhongguancun Bio-pharmaceutical R&D Outsourcing Alliance
3.5.3 Shanghai Pudong Bio-Pharmaceutical R&D Outsourcing Service Alliance
3.5.4 CROSA
3.5.5 Chengdu Bio-pharmaceutical R&D Outsourcing Alliance

4. Regional Market
4.1 Beijing
4.1.1 Pharmaceutical Manufacturing with Steady Growth
4.1.2 G20 Enterprises have Become the Core Strength of Industrial Development
4.1.3 R&D Services Industry Presents Prominent Contribution, with ABO Union Becoming an Important Force.
4.2 Shanghai
4.2.1 State Biotech & Pharmaceutical Industrial Base (Shanghai) (Zhangjiang Drug Valley)
4.3 Nanjing
4.3.1 Market Advantage
4.3.2 Development Prospects

5. Key CRO Enterprises Worldwide
5.1 COVANCE
5.1.1 Profile
5.1.2 Operation
5.1.3 Business in China
5.2 PAREXEL INTERNATIONAL
5.2.1 Profile
5.2.2 Business in China
5.3 PPD
5.3.1 Profile
5.3.2 Business in China
5.4 Quintiles Transnational
5.4.1 Profile
5.4.2 Business in China
5.5 Charles River Labs (CRL)
5.5.1 Profile
5.5.2 Business in China
5.6 Asymchem Inc
5.6.1 Profile
5.6.2 Asymchem Laboratories (Tianjin) Co. Ltd.
5.6.3 Asymchem Life Science (Tianjin) Co., Ltd.
5.7 MDS Inc.
5.7.1 Profile
5.7.2 MDS Pharma Services (China) Inc.

6.Key CRO Enterprises in China
6.1 WuXi AppTec Co., Ltd.
6.1.1 Profile
6.1.2 Operation
6.1.3 Business Structure
6.1.4 Development
6.2 ShangPharma Corp
6.2.1 Profile
6.2.2 Operation
6.2.3 Development
6.2.4 Shanghai ChemPartner Co. Ltd
6.2.5 Shanghai ChemExplorer Co. Ltd
6.2.6 Chengdu China Gateway Pharmaceutical Development Co. Ltd
6.3 Venturepharm Laboratories Limited
6.3.1 Profile
6.3.2 Operation
6.3.3 Development
6.4 Sundia MediTech Co., Ltd
6.5 Chemizon (Beijing) Pharma-Tech Co., Ltd
6.6 Excel PharmaStudies Co. Ltd
6.7 Tigermed Pharma-Tech Co., Ltd

Selected Charts
Classification of CRO
Market Size and Growth Rate of Global CRO, 2007-2010
Global Key CRO Organizations and Their Business
Industrial Sales Output Value and Growth Rate of Pharmaceutical Manufacturing Industry in China, 2008-Apr. 2011
Output Value of New Products of Pharmaceutical Manufacturing Industry in China, 2008-2010
Classification of Chinese CRO Companies (by Business)
Market Size and Growth Rate of CRO in China, 2007-2010
Key M&A Cases of CRO Industry in China, 2007-2011
Orders and Revenue of ABO Union and Proportions in International Orders ,2008-2010
Key Members and Unique Services of ABO Union
Sponsor of Zhongguancun CRO Union (in no particular order)
Biopharmaceutical CRO Companies in Shanghai Pudong New Area
CRO Service Chain of Shanghai Pudong Zhangjiang
Operating Income and Total Profit of Beijing Pharmaceutical Industry by Sector, 2010
Advantageous Fields of Beijing CRO Services
Platform Edge of Zhangjiang Drug Valley
List of Major CRO Companies of Zhangjiang Drug Valley, Shanghai
Industry Advantages of CRO Nanjing
Operating Income and Gross Margin of Covance, 2007-2010
Operating Income of Covance (by Business), 2008-2010
Operating Income of PAREXEL, 2007-2010
Revenue of PAREXEL Worldwide (by Region), 2008-2010
Operating Income of PPD, 2007-2010
Sales of CRL, 2007-2010
Companies of Asymchem Inc in China and Major Business
Operation of Asymchem Laboratories (Tianjin), 2008 and Jan. 2009- May 2009
Operation of Asymchem Life Science (Tianjin), 2008
Major Facilities of WuXi AppTec
Sales and Gross Margin of WuXi AppTec, 2008-2010
Sales of WuXi AppTec (By Business), 2010
Main Bases of ShangPharma Corp
Net Income and Gross Profit of ShangPharma Corp, 2008-2010
Net Income of ShangPharma Corp Worldwide (by Region), 2007-2009
Revenue and Gross Profit of Venturepharm Laboratories Limited, 2007- Jan.- Mar.2011
Operation of Venturepharm Laboratories Limited, 2007-Jan.- Mar.2011
Patents Applied by Venturepharm Laboratories Limited
Strength of Excel PharmaStudies
Main Clients of Tigermed Pharma-Tech